This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Nov 18;149(5):11.

Review: rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy

Joe Alcorn¹

Affiliations

PMID: 19014178

Comment

Review: rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy

Joe Alcorn. ACP J Club. 2008.

. 2008 Nov 18;149(5):11.

Author

Joe Alcorn¹

Affiliation

¹ University of New Mexico, Albuquerque, New Mexico, USA.

PMID: 19014178

No abstract available

PubMed Disclaimer

Comment on

Rifaximin for the treatment of hepatic encephalopathy.
Lawrence KR, Klee JA. Lawrence KR, et al. Pharmacotherapy. 2008 Aug;28(8):1019-32. doi: 10.1592/phco.28.8.1019. Pharmacotherapy. 2008. PMID: 18657018 Review.

Similar articles

Review: lactulose or lactitol may improve hepatic encephalopathy but may be less effective than antibiotics.
Korula J. Korula J. ACP J Club. 2004 Nov-Dec;141(3):59. ACP J Club. 2004. PMID: 15518443 No abstract available.
Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
Sharma BC, Sharma P, Agrawal A, Sarin SK. Sharma BC, et al. Gastroenterology. 2009 Sep;137(3):885-91, 891.e1. doi: 10.1053/j.gastro.2009.05.056. Epub 2009 Jun 6. Gastroenterology. 2009. PMID: 19501587 Clinical Trial.
Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
Sharma P, Sharma BC, Sarin SK. Sharma P, et al. Liver Int. 2009 Oct;29(9):1365-71. doi: 10.1111/j.1478-3231.2009.02067.x. Epub 2009 Jun 23. Liver Int. 2009. PMID: 19555401
Management options for minimal hepatic encephalopathy.
Bajaj JS. Bajaj JS. Expert Rev Gastroenterol Hepatol. 2008 Dec;2(6):785-90. doi: 10.1586/17474124.2.6.785. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19090738 Review.
Treatment of portal systemic encephalopathy: standard and new treatments.
Marín E, Uribe M. Marín E, et al. Rev Invest Clin. 1990 Jul;42 Suppl:141-8. Rev Invest Clin. 1990. PMID: 19256154 Review.

See all similar articles

Cited by

Comparative Analysis of the Efficacy of Different Regimens of 12 Months Rifaximin-Alfa Therapy in Patients with Liver Cirrhosis and Minimal Hepatic Encephalopathy.
Bakulin IG, Ivanova KN, Eremina EY, Marchenko NV; NORMIND study team. Bakulin IG, et al. Diagnostics (Basel). 2023 Oct 17;13(20):3239. doi: 10.3390/diagnostics13203239. Diagnostics (Basel). 2023. PMID: 37892060 Free PMC article.
Rifaximin in the treatment of hepatic encephalopathy.
Iadevaia MD, Prete AD, Cesaro C, Gaeta L, Zulli C, Loguercio C. Iadevaia MD, et al. Hepat Med. 2011 Dec 22;3:109-17. doi: 10.2147/HMER.S11988. Hepat Med. 2011. PMID: 24367227 Free PMC article. Review.
Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats.
Odena G, Miquel M, Serafín A, Galan A, Morillas R, Planas R, Bartolí R. Odena G, et al. World J Gastroenterol. 2012 May 7;18(17):2084-91. doi: 10.3748/wjg.v18.i17.2084. World J Gastroenterol. 2012. PMID: 22563196 Free PMC article.
Rifaximin therapy and hepatic encephalopathy: Pros and cons.
Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Zullo A, et al. World J Gastrointest Pharmacol Ther. 2012 Aug 6;3(4):62-7. doi: 10.4292/wjgpt.v3.i4.62. World J Gastrointest Pharmacol Ther. 2012. PMID: 22966484 Free PMC article.
Antibiotics for the treatment of hepatic encephalopathy.
Patidar KR, Bajaj JS. Patidar KR, et al. Metab Brain Dis. 2013 Jun;28(2):307-12. doi: 10.1007/s11011-013-9383-5. Epub 2013 Feb 8. Metab Brain Dis. 2013. PMID: 23389621 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions